NewsRoom Articles - Page 98 of 154 - PsychedelicNewsWire (PNW)

MondayMay 17, 2021 3:30 pm

Texas House Passes Psychedelics Research Law

The House of Representatives in Texas passed a bill last week that would mandate the state to undertake research regarding the potential of different psychedelic substances, such as MDMA and psilocybin. The bill, whose chief sponsor was Rep. Alex Dominguez, a Democrat, was supported by 134 House members while 12 opposed it. The passage of the bill now means it heads to the state Senate for consideration. During an earlier Public Health House Committee meeting, legislators modified the scope of this expected research to cover only military veterans suffering from PTSD rather than leaving the bill with its previously wide…

FridayMay 14, 2021 2:00 pm

Maine Senate Bill Could Legalize Psilocybin Mushroom Therapy for Adults

A bill that was recently introduced in Maine will legalize psilocybin’s therapeutic use and establish a licensed industry for the drug. Psilocybin is the main active compound found in magic mushrooms. Introduced by State Sen. Donna Bailey, the Maine Psilocybin Services Act will permit individuals aged 21 and above to legally buy psilocybin products and ingest them under the supervision of psilocybin service providers who are licensed. The measure, whose purpose is to expand the access to psilocybin to help manage depression and anxiety, along with other mental health conditions, cites no specific medical diagnosis that individuals will need in…

FridayMay 14, 2021 12:05 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Maintains Buy Rating in Recent Equity Update

April analyst reports all point to a bright future for Cybin “CYBN is a true multi-molecule company that's not being reflected in its valuation,” reports Stifel “With a relatively small 5% penetration, Cybin could achieve ~$8B in sales in the U.S. and EU5 combined,” notes Roth A series of recent analyst reports bodes well for Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing psychedelic therapeutics. April reports from Canaccord Genuity equity research company, Stifel GMP (https://ibn.fm/aQ9af) and Roth Capital Partners (https://ibn.fm/YkBNb) all categorize Cybin as a buy, with Stifel increasing its price target from $5 to…

ThursdayMay 13, 2021 2:30 pm

Ontario Cannabis Company Requests Government Permission to Produce, Study Psychedelic Substances

New Leaf Canada has requested an exemption under the federal drug laws to allow it to construct a lab meant for the production and study of psychedelic substances. The marijuana company, which is based in Toronto, announced that if its request is approved, the company will commence the expansion of its marijuana production facility, which is located in Norfolk Country, Ontario. The lab will adjoin its current production facility and will be utilized in the production of psilocin and psilocybin. The two substances are active compounds found in hallucinogenic mushrooms, which are currently illegal in Canada. Despite the illegal status…

ThursdayMay 13, 2021 12:05 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Builds Alliances Ahead of Psychedelic Drug Trial for Eating Disorders

Orphan-stage pharmaceutical innovator Tryp Therapeutics is dedicated to developing novel therapies for medical conditions with unmet needs Tryp’s embrace of psychedelic drug potential is demonstrated in its advancing clinical trials seeking an answer to eating disorders such as binge eating and hyperphagia The company is also developing a clinical trial to address the needs of fibromyalgia patients who often rely on opioids to relieve their symptoms Tryp has announced two new collaborations for oversight of the drug trials this month; consultants with Fluence and Clinlogix will help to ensure the quality of the tests Bioscience pharmaceutical company Tryp Therapeutics (CSE:…

WednesdayMay 12, 2021 12:15 pm

At-Home Genetics Test May Help Detect Possible Psychedelic Therapy Risks

Psychedelics are making a comeback in Western society, having started the journey to mainstream a few years ago. This renaissance has brought with it a lot of new discoveries, many of which are useful for the mental health field. As mental health disorders increase at a rather alarming rate, the research on various psychedelics as potential alternative treatments has been welcomed by many, especially those in the psychedelic field and those who would like to indulge in psychedelics as well as users of these substances. However, as with any other drug, psychedelics carry some risk, and with more jurisdictions beginning…

TuesdayMay 11, 2021 2:30 pm

Minnesota Clinic Provides Model for Therapeutic Use of Psychedelics

Since selective serotonin reuptake inhibitor antidepressants (“SSRIs”) were introduced in the late ‘80s, little has changed in how different mental health conditions are treated. The co-founder of the Institute for Integrative Therapies (“IIT”) Manoj Doss notes that there haven’t been many breakthroughs in the psychiatry field in the recent past. Doss, who is certified in both general and occupational medicine, asserts that a need exists to re-examine how mental illnesses are treated, adding that the treatments used need to be more effective. This is why he and his co-founder, Kyle Keller, are trying to approach the treatment of various mental…

TuesdayMay 11, 2021 1:17 pm

Business Booming in April: Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Lands Tolling Agreement to Extract CBD from 500 Kg Hemp Biomass

CBD-infused products market is expected to grow 48.1% annually to reach $165.7 billion by 2027 Pure Extracts Technologies’ subsidiary recently began production of goods expected to generate approximately $950,000 in revenue New tolling agreement is for extraction of 80-85% pure CBD distillate from an initial 500 kilograms (~1,102 pounds) of hemp biomass Any industry forecast for double-digit growth is one worth keeping an eye on. When experts are calling for mid-double-digit annual market growth, like that of CBD-infused products, it’s worth a head turn and a stare. Meticulous Research this month forecast this market to experience compound annual growth of…

MondayMay 10, 2021 12:10 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Looks to New Senior Management with Expertise in Development, Clinical Capabilities

Company committed to building presence in U.S. and Europe to advance mission of improving mental health care New appointments will strengthen Cybin’s development and clinical operations globally, solidify position within the industry New leaders bring broad experience, deep insight to their new roles Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing psychedelic therapeutics, recently made key senior-management changes designed to provide the company with added insight and expertise in the expansion of its development and clinical operations in the United States and Europe (https://ibn.fm/FsF0L). The appointments, which are effective immediately, call for Alexander Belser, PhD, to…

MondayMay 10, 2021 11:00 am

Researchers Have Designed a Sensor to Detect Psychedelics That Aren’t Hallucinogenic

Researchers have come up with a way to determine if a molecule can induce hallucinations, without testing it on animals or people. Evidence from prior research has suggested that psychedelic compounds could be used to manage psychiatric conditions such as PTSD. Scientists are therefore looking for ways to retain the beneficial properties of psychedelic drugs but get rid of their hallucinogenic side effects, which can make treatment more challenging. At the moment, it isn’t possible to forecast whether a drug can give rise to hallucinations before researchers carry out tests on people or animals. University of California chemical neuroscientist David…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000